Viva Biotech Reports 2026 Interim Results: AI Accelerates Drug R&D, CDMO Growth Fuels Revenue
Viva Biotech announced its 2026 interim results, showing increased revenue driven by AI in drug R&D and accelerated commercial manufacturing services.
Viva Biotech has released its interim results for the period ending June 30, 2026, highlighting the impact of artificial intelligence on its drug research and development pipeline and growth in its contract development and manufacturing organization (CDMO) services.
The company reported revenue of RMB 1,006.5 million, a 21.0% year-over-year increase. Gross profit reached RMB 341.7 million, marking a 0.7% increase from the previous year, with a gross profit margin of 34.0%.
These results suggest Viva Biotech is integrating AI to streamline its drug discovery and development processes, potentially leading to faster timelines for new therapeutics. The company's focus on commercial manufacturing also appears to be a key driver of its financial performance.
The continued expansion of its CDMO business indicates Viva Biotech's capacity to support clients through various stages of drug development and production. The company's strategic approach appears to be yielding positive financial outcomes as it scales its operations.